Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista
October 03, 2016 at 11:57 AM EDT
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta ...
